These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 28406860)

  • 1. PREDICTIVE VALUE OF OPTICAL COHERENCE TOMOGRAPHIC FEATURES IN THE BEVACIZUMAB AND RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA (BRDME) STUDY.
    Fickweiler W; Schauwvlieghe AME; Schlingemann RO; Maria Hooymans JM; Los LI; Verbraak FD;
    Retina; 2018 Apr; 38(4):812-819. PubMed ID: 28406860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CORRELATION OF OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI WITH VISUAL OUTCOMES IN DIFFERENT PATTERNS OF DIABETIC MACULAR EDEMA.
    Kang JW; Chung H; Chan Kim H
    Retina; 2016 Sep; 36(9):1630-9. PubMed ID: 26900741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
    Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
    Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OPTICAL COHERENCE TOMOGRAPHY BASELINE PREDICTORS FOR INITIAL BEST-CORRECTED VISUAL ACUITY RESPONSE TO INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN EYES WITH DIABETIC MACULAR EDEMA: The CHARTRES Study.
    Santos AR; Costa MÂ; Schwartz C; Alves D; Figueira J; Silva R; Cunha-Vaz JG
    Retina; 2018 Jun; 38(6):1110-1119. PubMed ID: 28613220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RETINAL LAYER RESPONSE TO RANIBIZUMAB DURING TREATMENT OF DIABETIC MACULAR EDEMA: Thinner is Not Always Better.
    Ebneter A; Wolf S; Abhishek J; Zinkernagel MS
    Retina; 2016 Jul; 36(7):1314-23. PubMed ID: 26735563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HYPERREFLECTIVE RETINAL SPOTS AND VISUAL FUNCTION AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT IN CENTER-INVOLVING DIABETIC MACULAR EDEMA.
    Vujosevic S; Berton M; Bini S; Casciano M; Cavarzeran F; Midena E
    Retina; 2016 Jul; 36(7):1298-308. PubMed ID: 26689274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema.
    Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R
    Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Intravitreal Ranibizumab on Intraretinal Hard Exudates in Eyes with Diabetic Macular Edema.
    Srinivas S; Verma A; Nittala MG; Alagorie AR; Nassisi M; Gasperini J; Sadda SR
    Am J Ophthalmol; 2020 Mar; 211():183-190. PubMed ID: 31758926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Crossover Design for Comparative Efficacy: A 36-Week Randomized Trial of Bevacizumab and Ranibizumab for Diabetic Macular Edema.
    Wiley HE; Thompson DJ; Bailey C; Chew EY; Cukras CA; Jaffe GJ; Lee RW; Loken EK; Meyerle CB; Wong W; Ferris FL
    Ophthalmology; 2016 Apr; 123(4):841-9. PubMed ID: 26875003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study).
    Ehrlich R; Pokroy R; Segal O; Goldstein M; Pollack A; Hanhart J; Barak Y; Kehat R; Shulman S; Vidne O; Abu Ahmad W; Chowers I
    Eur J Ophthalmol; 2019 Mar; 29(2):229-233. PubMed ID: 29916263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response of Retinal Sensitivity to Intravitreal Anti-angiogenic Bevacizumab and Triamcinolone Acetonide for Patients with Diabetic Macular Edema over One Year.
    Mylonas G; Schranz M; Scholda C; Karst S; Reiter G; Baumann L; Schmidt-Erfurth U; Kriechbaum K
    Curr Eye Res; 2020 Sep; 45(9):1107-1113. PubMed ID: 31961224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectral domain optical coherence tomography predictors of visual outcome in diabetic cystoid macular edema after bevacizumab injection.
    Al Faran A; Mousa A; Al Shamsi H; Al Gaeed A; Ghazi NG
    Retina; 2014 Jun; 34(6):1208-15. PubMed ID: 24368308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROSPECTIVE RANDOMIZED SUBJECT-MASKED STUDY OF INTRAVITREAL BEVACIZUMAB MONOTHERAPY VERSUS DEXAMETHASONE IMPLANT MONOTHERAPY IN THE TREATMENT OF PERSISTENT DIABETIC MACULAR EDEMA.
    Shah SU; Harless A; Bleau L; Maturi RK
    Retina; 2016 Oct; 36(10):1986-96. PubMed ID: 27124881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The macular function and structure in patients with diabetic macular edema before and after ranibizumab treatment.
    Nowacka B; Kirkiewicz M; Mozolewska-Piotrowska K; Lubiński W
    Doc Ophthalmol; 2016 Apr; 132(2):111-22. PubMed ID: 27000269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
    Ozkaya A; Demir G; Kirmaci A
    Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of inner and outer retinal thickness in patients receiving intravitreal ranibizumab injections for diabetic macular edema.
    Dursun A; Ozec AV; Kirboga K; Dursun FG; Toker MI; Erdogan H; Arici MK
    Eur J Ophthalmol; 2016; 26(1):48-53. PubMed ID: 26220809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-MONTH, SINGLE-MASKED, RANDOMIZED CONTROLLED STUDY OF EYES WITH PERSISTENT DIABETIC MACULAR EDEMA AFTER MULTIPLE ANTI-VEGF INJECTIONS TO ASSESS THE EFFICACY OF THE DEXAMETHASONE-DELAYED DELIVERY SYSTEM AS AN ADJUNCT TO BEVACIZUMAB COMPARED WITH CONTINUED BEVACIZUMAB MONOTHERAPY.
    Maturi RK; Bleau L; Saunders J; Mubasher M; Stewart MW
    Retina; 2015 Aug; 35(8):1604-14. PubMed ID: 25829346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab.
    Wood EH; Karth PA; Moshfeghi DM; Leng T
    Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):950-4. PubMed ID: 26469235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.